Cidofovir Anhydrous: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Cidofovir Anhydrous. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Proteinuria (≥ 100 mg/dl) | 50% |
| Neutropenia (≤ 500 cells/mm3 ) | 24% |
| Decreased serum bicarbonate (≤ 16 meq/l) | 16% |
| Fever | 14% |
| Infection | 12% |
| Creatinine elevation (≥ 2.0 mg/dl) | 12% |
| Pneumonia | 9% |
| Dyspnea | 8% |
| Nausea with vomiting | 7% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Cidofovir is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). THE SAFETY AND EFFICACY OF CIDOFOVIR INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (SUCH AS PNEUMONITIS OR GASTROENTERITIS), CONGENITAL OR NEONATAL CMV DISEASE, OR CMV DISEASE IN NON-HIV-INFECTED INDIVIDUALS.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.
Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.
Compare lab testing options near you ↗ (affiliate link)